An Open Label, Single Arm, Phase I Clinical Study Assessing Safety, Tolerability, and Efficacy of MVX-ONCO-2 in Patients With Advanced Solid Tumors
Latest Information Update: 01 Feb 2023
At a glance
- Drugs MVX-ONCO-2 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors MaxiVax
- 27 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2022 Planned End Date changed from 1 May 2027 to 1 Dec 2027.
- 23 Aug 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Jul 2023.